SciBX
Science-Business eXchange

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Assays & screens			
NMR-based detection of allosteric v-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1) agonists and antagonists	An NMR-based conformational assay could help identify allosteric ABL1-targeting compounds to treat chronic myelogenous leukemia (CML) and other blood cancers. The assay detects conformational changes in a C-terminal helix in ABL1 following binding of a compound to an allosteric site. The assay distinguishes antagonists from agonists—if the C-terminal helix bends, the compound is an antagonist, whereas if the helix does not bend, the compound is an agonist. Next steps could include using the assay to identify new ABL1 modulators from chemical libraries. *SciBX* 3(21); doi:10.1038/scibx.2010.661 Published online May 27, 2010	Patent and licensing status unavailable	Jahnke, W. *et al. J. Am. Chem. Soc.*; published online May 7, 2010; doi:10.1021/ja101837n **Contact:** Wolfgang Jahnke, Novartis Institutes for Biomedical Research, Basel, Switzerland e-mail: wolfgang.jahnke@novartis.com